Departments of Medicine and Infectious Diseases, Barwon Health, Geelong, Vic., Australia.
Division of Epidemiology, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel.
Clin Microbiol Infect. 2016 May;22(5):416-22. doi: 10.1016/j.cmi.2015.12.002. Epub 2015 Dec 17.
Antibacterial therapy is one of the most important medical developments of the twentieth century; however, the spread of resistance in healthcare settings and in the community threatens the enormous gains made by the availability of antibiotic therapy. Infections caused by resistant bacteria lead to up to two-fold higher rates of adverse outcomes compared with similar infections caused by susceptible strains. These adverse outcomes may be clinical or economic and reflect primarily the failure or delay of antibiotic treatment. The magnitude of these adverse outcomes will be more pronounced as disease severity, strain virulence, or host vulnerability increases. The negative impacts of antibacterial resistance can be measured at the patient level by increased morbidity and mortality, at the healthcare level by increased resource utilization, higher costs and reduced hospital activity and at the society level by antibiotic treatment guidelines favouring increasingly broad-spectrum empiric therapy. In this review we will discuss the negative impact of antibiotic resistance on patients, the healthcare system and society.
抗菌治疗是 20 世纪最重要的医学发展之一;然而,在医疗机构和社区中,耐药性的传播威胁到抗生素治疗的巨大收益。与敏感菌株引起的类似感染相比,耐药菌引起的感染导致不良后果的发生率增加了一倍。这些不良后果可能是临床或经济方面的,主要反映了抗生素治疗的失败或延迟。随着疾病严重程度、菌株毒力或宿主脆弱性的增加,这些不良后果的程度将更加明显。抗菌耐药性的负面影响可以在患者层面上通过发病率和死亡率的增加、医疗保健层面上通过资源利用的增加、成本的增加以及医院活动的减少以及社会层面上通过抗生素治疗指南来衡量,这些指南有利于越来越广泛的经验性治疗。在这篇综述中,我们将讨论抗生素耐药性对患者、医疗保健系统和社会的负面影响。
Clin Microbiol Infect. 2015-12-17
Curr Opin Infect Dis. 2011-2
Curr Opin Infect Dis. 2011-2
Adv Drug Deliv Rev. 2005-7-29
J Infect Dev Ctries. 2014-9-12
Clin Microbiol Infect. 2014-11-7
Infect Dis Clin North Am. 2016-6
Infect Drug Resist. 2025-8-27
One Health. 2025-6-26